Stem definition | Drug id | CAS RN |
---|---|---|
HIV protease inhibitors | 254 | 198904-31-3 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.30 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 8.11 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 64 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 2, 2004 | EMA | ||
June 20, 2003 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Maternal exposure during pregnancy | 1382.73 | 72.45 | 321 | 1680 | 14542 | 2341542 |
Abortion spontaneous | 1081.79 | 72.45 | 259 | 1742 | 13186 | 2342898 |
Foetal exposure during pregnancy | 1009.32 | 72.45 | 207 | 1794 | 5045 | 2351039 |
Exposure during pregnancy | 743.74 | 72.45 | 220 | 1781 | 24999 | 2331085 |
Live birth | 598.29 | 72.45 | 107 | 1894 | 1184 | 2354900 |
Premature baby | 383.69 | 72.45 | 86 | 1915 | 3118 | 2352966 |
Pregnancy | 375.93 | 72.45 | 101 | 1900 | 7848 | 2348236 |
Abortion induced | 361.53 | 72.45 | 83 | 1918 | 3353 | 2352731 |
Stillbirth | 335.29 | 72.45 | 67 | 1934 | 1374 | 2354710 |
Caesarean section | 331.78 | 72.45 | 80 | 1921 | 4001 | 2352083 |
Hyperbilirubinaemia | 330.46 | 72.45 | 67 | 1934 | 1482 | 2354602 |
Premature delivery | 297.76 | 72.45 | 70 | 1931 | 3130 | 2352954 |
Normal newborn | 194.67 | 72.45 | 42 | 1959 | 1258 | 2354826 |
Foetal growth restriction | 188.67 | 72.45 | 40 | 1961 | 1100 | 2354984 |
Nephrolithiasis | 182.93 | 72.45 | 51 | 1950 | 4492 | 2351592 |
Jaundice | 182.05 | 72.45 | 53 | 1948 | 5455 | 2350629 |
Pregnancy on contraceptive | 151.07 | 72.45 | 27 | 1974 | 291 | 2355793 |
Congenital naevus | 147.31 | 72.45 | 20 | 1981 | 20 | 2356064 |
Hepatitis | 141.00 | 72.45 | 45 | 1956 | 6292 | 2349792 |
Blood bilirubin increased | 139.99 | 72.45 | 43 | 1958 | 5302 | 2350782 |
Foetal death | 137.32 | 72.45 | 34 | 1967 | 1878 | 2354206 |
Renal colic | 133.00 | 72.45 | 24 | 1977 | 274 | 2355810 |
Ventricular septal defect | 120.17 | 72.45 | 26 | 1975 | 786 | 2355298 |
Low set ears | 119.60 | 72.45 | 18 | 1983 | 56 | 2356028 |
Acoustic stimulation tests abnormal | 105.78 | 72.45 | 15 | 1986 | 26 | 2356058 |
Pre-eclampsia | 104.23 | 72.45 | 26 | 1975 | 1478 | 2354606 |
Supernumerary nipple | 100.51 | 72.45 | 13 | 1988 | 5 | 2356079 |
Viral mutation identified | 97.35 | 72.45 | 18 | 1983 | 237 | 2355847 |
Patent ductus arteriosus | 96.47 | 72.45 | 21 | 1980 | 653 | 2355431 |
Virologic failure | 95.29 | 72.45 | 18 | 1983 | 268 | 2355816 |
Lipodystrophy acquired | 94.49 | 72.45 | 18 | 1983 | 281 | 2355803 |
Drug resistance | 94.36 | 72.45 | 27 | 1974 | 2597 | 2353487 |
Immune reconstitution inflammatory syndrome | 93.72 | 72.45 | 23 | 1978 | 1221 | 2354863 |
Eosinophilia | 91.05 | 72.45 | 27 | 1974 | 2943 | 2353141 |
Premature rupture of membranes | 90.28 | 72.45 | 21 | 1980 | 885 | 2355199 |
Twin pregnancy | 89.26 | 72.45 | 17 | 1984 | 265 | 2355819 |
Drug interaction | 88.19 | 72.45 | 50 | 1951 | 29113 | 2326971 |
Low birth weight baby | 86.77 | 72.45 | 20 | 1981 | 809 | 2355275 |
Premature labour | 86.28 | 72.45 | 24 | 1977 | 2082 | 2354002 |
Placental insufficiency | 84.46 | 72.45 | 16 | 1985 | 242 | 2355842 |
Oligohydramnios | 83.85 | 72.45 | 20 | 1981 | 940 | 2355144 |
Gestational diabetes | 81.39 | 72.45 | 21 | 1980 | 1366 | 2354718 |
Placenta praevia | 79.11 | 72.45 | 15 | 1986 | 228 | 2355856 |
Polydactyly | 76.52 | 72.45 | 13 | 1988 | 101 | 2355983 |
Renal failure | 75.68 | 72.45 | 38 | 1963 | 17311 | 2338773 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nephrolithiasis | 772.93 | 43.08 | 183 | 2477 | 3809 | 1740312 |
Hyperbilirubinaemia | 630.45 | 43.08 | 140 | 2520 | 2147 | 1741974 |
Foetal exposure during pregnancy | 603.09 | 43.08 | 165 | 2495 | 6194 | 1737927 |
Jaundice | 490.35 | 43.08 | 139 | 2521 | 5923 | 1738198 |
Renal colic | 475.18 | 43.08 | 85 | 2575 | 377 | 1743744 |
Lipodystrophy acquired | 425.79 | 43.08 | 75 | 2585 | 298 | 1743823 |
Blood bilirubin increased | 372.26 | 43.08 | 113 | 2547 | 6097 | 1738024 |
Drug interaction | 253.47 | 43.08 | 129 | 2531 | 27829 | 1716292 |
Immune reconstitution inflammatory syndrome | 216.99 | 43.08 | 55 | 2605 | 1494 | 1742627 |
Acute kidney injury | 186.71 | 43.08 | 114 | 2546 | 34830 | 1709291 |
Ocular icterus | 181.85 | 43.08 | 40 | 2620 | 574 | 1743547 |
Cholelithiasis | 169.67 | 43.08 | 53 | 2607 | 3112 | 1741009 |
Renal tubular disorder | 162.56 | 43.08 | 39 | 2621 | 836 | 1743285 |
Premature baby | 160.76 | 43.08 | 50 | 2610 | 2892 | 1741229 |
Renal failure | 154.07 | 43.08 | 83 | 2577 | 19934 | 1724187 |
Hepatitis | 146.36 | 43.08 | 53 | 2607 | 4902 | 1739219 |
Osteonecrosis | 146.14 | 43.08 | 50 | 2610 | 3912 | 1740209 |
Calculus urinary | 144.07 | 43.08 | 29 | 2631 | 262 | 1743859 |
Mitochondrial toxicity | 142.03 | 43.08 | 27 | 2633 | 175 | 1743946 |
Nausea | 136.32 | 43.08 | 109 | 2551 | 51087 | 1693034 |
Alanine aminotransferase increased | 132.44 | 43.08 | 64 | 2596 | 12214 | 1731907 |
Eyelid ptosis | 117.23 | 43.08 | 29 | 2631 | 708 | 1743413 |
Lipoatrophy | 117.17 | 43.08 | 21 | 2639 | 93 | 1744028 |
Depression | 95.30 | 43.08 | 57 | 2603 | 16612 | 1727509 |
Aspartate aminotransferase increased | 95.02 | 43.08 | 49 | 2611 | 10707 | 1733414 |
Viral load increased | 92.97 | 43.08 | 23 | 2637 | 561 | 1743560 |
Renal impairment | 91.55 | 43.08 | 50 | 2610 | 12264 | 1731857 |
Drug resistance | 89.53 | 43.08 | 33 | 2627 | 3197 | 1740924 |
Hepatic cirrhosis | 84.35 | 43.08 | 30 | 2630 | 2623 | 1741498 |
Hydronephrosis | 82.47 | 43.08 | 25 | 2635 | 1320 | 1742801 |
Dysphagia | 80.32 | 43.08 | 43 | 2617 | 10125 | 1733996 |
Kaposi's sarcoma | 79.33 | 43.08 | 22 | 2638 | 845 | 1743276 |
Pancreatitis | 78.98 | 43.08 | 38 | 2622 | 7149 | 1736972 |
Diarrhoea | 76.77 | 43.08 | 81 | 2579 | 53771 | 1690350 |
Pyrexia | 75.56 | 43.08 | 75 | 2585 | 46325 | 1697796 |
Proteinuria | 74.93 | 43.08 | 28 | 2632 | 2816 | 1741305 |
Osteoporosis | 74.78 | 43.08 | 24 | 2636 | 1531 | 1742590 |
Myocardial infarction | 74.37 | 43.08 | 59 | 2601 | 27115 | 1717006 |
Diplopia | 73.96 | 43.08 | 27 | 2633 | 2543 | 1741578 |
Ureterolithiasis | 70.99 | 43.08 | 17 | 2643 | 360 | 1743761 |
Blood bilirubin unconjugated increased | 70.68 | 43.08 | 15 | 2645 | 179 | 1743942 |
Tubulointerstitial nephritis | 70.26 | 43.08 | 27 | 2633 | 2931 | 1741190 |
Fatigue | 68.13 | 43.08 | 74 | 2586 | 50707 | 1693414 |
Weight decreased | 67.85 | 43.08 | 52 | 2608 | 22701 | 1721420 |
Hepatic steatosis | 62.85 | 43.08 | 24 | 2636 | 2560 | 1741561 |
Depressed mood | 62.71 | 43.08 | 25 | 2635 | 2991 | 1741130 |
Haematuria | 62.57 | 43.08 | 33 | 2627 | 7527 | 1736594 |
Diabetes mellitus | 62.46 | 43.08 | 32 | 2628 | 6876 | 1737245 |
Vomiting | 62.41 | 43.08 | 62 | 2598 | 38253 | 1705868 |
Fanconi syndrome | 62.26 | 43.08 | 15 | 2645 | 326 | 1743795 |
Anaemia | 62.04 | 43.08 | 55 | 2605 | 29402 | 1714719 |
Hepatomegaly | 61.01 | 43.08 | 21 | 2639 | 1664 | 1742457 |
Exposure during pregnancy | 60.84 | 43.08 | 24 | 2636 | 2793 | 1741328 |
Nephropathy toxic | 60.44 | 43.08 | 21 | 2639 | 1711 | 1742410 |
Hyperlipidaemia | 58.91 | 43.08 | 22 | 2638 | 2207 | 1741914 |
Blood creatinine increased | 57.89 | 43.08 | 39 | 2621 | 13907 | 1730214 |
Rash | 56.42 | 43.08 | 59 | 2601 | 38634 | 1705487 |
Vanishing bile duct syndrome | 56.25 | 43.08 | 12 | 2648 | 147 | 1743974 |
Thrombocytopenia | 55.64 | 43.08 | 45 | 2615 | 21204 | 1722917 |
Lymphadenopathy | 55.23 | 43.08 | 25 | 2635 | 4089 | 1740032 |
Virologic failure | 54.72 | 43.08 | 14 | 2646 | 392 | 1743729 |
Cushing's syndrome | 53.75 | 43.08 | 15 | 2645 | 589 | 1743532 |
Blood antidiuretic hormone increased | 53.19 | 43.08 | 9 | 2651 | 26 | 1744095 |
Fanconi syndrome acquired | 52.69 | 43.08 | 14 | 2646 | 456 | 1743665 |
Pruritus | 52.14 | 43.08 | 45 | 2615 | 23177 | 1720944 |
Hypertension | 50.51 | 43.08 | 41 | 2619 | 19407 | 1724714 |
Myositis | 50.45 | 43.08 | 18 | 2642 | 1585 | 1742536 |
Abdominal pain | 48.96 | 43.08 | 42 | 2618 | 21448 | 1722673 |
Enanthema | 48.82 | 43.08 | 10 | 2650 | 99 | 1744022 |
Heterotaxia | 47.84 | 43.08 | 8 | 2652 | 21 | 1744100 |
Neonatal hyponatraemia | 47.84 | 43.08 | 8 | 2652 | 21 | 1744100 |
Liver disorder | 47.75 | 43.08 | 25 | 2635 | 5611 | 1738510 |
Hepatitis C | 47.30 | 43.08 | 20 | 2640 | 2776 | 1741345 |
Blood creatine phosphokinase increased | 47.20 | 43.08 | 29 | 2631 | 8827 | 1735294 |
Wrong dose | 45.76 | 43.08 | 9 | 2651 | 71 | 1744050 |
Ventricular septal defect | 45.71 | 43.08 | 14 | 2646 | 764 | 1743357 |
Cholestasis | 45.20 | 43.08 | 21 | 2639 | 3644 | 1740477 |
Hypertriglyceridaemia | 43.50 | 43.08 | 15 | 2645 | 1194 | 1742927 |
Source | Code | Description |
---|---|---|
ATC | J05AE08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors |
ATC | J05AR15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR23 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D017320 | HIV Protease Inhibitors |
MeSH PA | D011480 | Protease Inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drug |
FDA EPC | N0000175889 | Protease Inhibitor |
FDA MoA | N0000191272 | UGT1A1 Inhibitors |
FDA MoA | N0000191269 | UDP Glucuronosyltransferases Inhibitors |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Hepatic failure | contraindication | 59927004 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Hemophilia | contraindication | 90935002 | |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Kidney stone | contraindication | 95570007 | |
Chronic hepatitis C | contraindication | 128302006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Breastfeeding (mother) | contraindication | 413712001 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.91 | acidic |
pKa2 | 11.57 | acidic |
pKa3 | 4.94 | Basic |
pKa4 | 1.0 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 300MG BASE | EVOTAZ | BRISTOL-MYERS SQUIBB | N206353 | Jan. 29, 2015 | RX | TABLET | ORAL | 8148374 | Sept. 3, 2029 | TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cytochrome P450 1A2 | Enzyme | Ki | 4.92 | WOMBAT-PK | |||||
Cytochrome P450 2C9 | Enzyme | Ki | 4.92 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | Ki | 5.63 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 4.17 | CHEMBL | |||||
UDP-glucuronosyltransferase 1-1 | Enzyme | Ki | 5.72 | WOMBAT-PK | |||||
Pol polyprotein | Enzyme | INHIBITOR | Ki | 9.62 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | Ki | 8.58 | WOMBAT-PK | |||||
Reverse transcriptase/RNaseH | Enzyme | IC50 | 7.59 | CHEMBL | |||||
Protease | Enzyme | IC50 | 8.40 | CHEMBL |
ID | Source |
---|---|
D000069446 | MESH_DESCRIPTOR_UI |
4024316 | VUID |
N0000022320 | NUI |
C1145759 | UMLSCUI |
D01276 | KEGG_DRUG |
4MT4VIE29P | UNII |
229975-97-7 | SECONDARY_CAS_RN |
413591007 | SNOMEDCT_US |
343047 | RXNORM |
d04882 | MMSL |
413592000 | SNOMEDCT_US |
4024316 | VANDF |
000306 | NDDF |
CHEMBL1163 | ChEMBL_ID |
DB01072 | DRUGBANK_ID |
CHEMBL1200678 | ChEMBL_ID |
8181 | INN_ID |
DR7 | PDB_CHEM_ID |
CHEBI:37924 | CHEBI |
148192 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3622 | CAPSULE, GELATIN COATED | 300 mg | ORAL | NDA | 19 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3624 | CAPSULE, GELATIN COATED | 150 mg | ORAL | NDA | 19 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3631 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 19 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-3638 | POWDER | 50 mg | ORAL | NDA | 19 sections |
EVOTAZ | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0003-3641 | TABLET | 300 mg | ORAL | NDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5526 | CAPSULE | 150 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5527 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5528 | CAPSULE | 300 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6875 | CAPSULE | 300 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-860 | CAPSULE | 150 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-861 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-862 | CAPSULE | 300 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-171 | CAPSULE | 150 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-172 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-173 | CAPSULE | 300 mg | ORAL | ANDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4854 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4857 | CAPSULE, GELATIN COATED | 150 mg | ORAL | NDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5838 | CAPSULE, GELATIN COATED | 300 mg | ORAL | NDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-399 | CAPSULE | 300 mg | ORAL | ANDA | 19 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-710 | CAPSULE | 100 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-711 | CAPSULE | 150 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-712 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Atazanavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-713 | CAPSULE | 300 mg | ORAL | ANDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67296-1236 | CAPSULE, GELATIN COATED | 300 mg | ORAL | NDA | 18 sections |
ATAZANAVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-443 | CAPSULE, GELATIN COATED | 100 mg | ORAL | ANDA | 18 sections |
ATAZANAVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-444 | CAPSULE, GELATIN COATED | 150 mg | ORAL | ANDA | 18 sections |
ATAZANAVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-445 | CAPSULE, GELATIN COATED | 200 mg | ORAL | ANDA | 18 sections |
ATAZANAVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-446 | CAPSULE, GELATIN COATED | 300 mg | ORAL | ANDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69189-3624 | CAPSULE, GELATIN COATED | 150 mg | ORAL | NDA | 18 sections |
REYATAZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69189-3631 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 18 sections |